Clinical Trials Logo

Clinical Trial Summary

This is a randomized,controlled, double-blinded, phase 3 clinical study to evaluate the efficacy and safety of recombinant human urokinase(rhPro-UK) versus basic treatment for patients with acute ischaemic stroke in 4.5-6 hours after stroke onset.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03578822
Study type Interventional
Source Tasly Pharmaceuticals, Inc.
Contact Haiqing Song, M.D
Phone 13701390976
Status Recruiting
Phase Phase 3
Start date August 10, 2018
Completion date December 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03463551 - Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic Phase 2
Completed NCT02164357 - Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset N/A
Recruiting NCT01207336 - Combined tDCS+PNS After Acute Stroke Phase 2/Phase 3
Recruiting NCT03328403 - Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion N/A
Recruiting NCT03639922 - Imatinib in Acute Ischaemic Stroke Phase 3
Recruiting NCT03541668 - Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST) Phase 3
Recruiting NCT03354429 - THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death Phase 3
Completed NCT01994720 - [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] Phase 3
Terminated NCT01745692 - Pragmatic Ischaemic Stroke Thrombectomy Evaluation N/A